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ABSTRACT
Introduction: Fingolimod 0.5 mg is an orally
active sphingosine 1-phosphate receptor
modulator approved for use in adults with
relapsing multiple sclerosis (MS). The efficacy
and safety profile of fingolimod has been well
characterized in a large clinical development
program. Here, we report the safety and
tolerability of fingolimod in relapsing-
remitting MS (RRMS) patients from Latin
America.
Methods: A total of 162 patients with RRMS,
predominantly from Latin American countries
(138/162), were enrolled in this 16-week, single
treatment arm, open-label, multi-center study.
Unlike the phase III pivotal studies, this study
permitted enrollment of patients with
controlled diabetes, certain cardiac and
pulmonary conditions, older age, and higher
baseline Expanded Disability Status Scale. All
patients were monitored clinically for a
minimum of 6 hours after the first dose. Safety
and tolerability assessments were based on
adverse events, clinically notable laboratory
abnormalities, vital signs, ophthalmic
examinations, and electrocardiograms.
Results: Overall, the safety and tolerability
profile was consistent with that reported
previously in phase 3 studies and the FIRST
study. Adverse events (AEs) were predominantly
mild (n = 49, 35.5%) or moderate (n = 27,
19.6%). Three patients (2.2%) discontinued
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fingolimod due to AEs. Infections were reported
in 33 patients (23.9%) and were predominantly
mild in nature (n = 28, 20.3%). Increases in
alanine aminotransferase enzymes of C3, C5
and C10 upper limit of normal were reported in
five (3.7%), three (2.2%) and one (0.7%)
patients, respectively. Hypertension cases
(n = 3; 2.2%) did not result in treatment
discontinuation and were controlled with
antihypertensive therapy. Following first-dose
administration, the majority of patients (90.6%)
were discharged at 6 h. During the first-dose
monitoring, 5 cases of bradycardia were
reported; none required extended monitoring
or treatment for symptomatic bradycardia.
Conclusion: The first dose of fingolimod 0.5 mg
was well tolerated in RRMS patients from Latin
America. The overall safety profile was clinically






observations; FIRST LATAM; Latin American;
Relapsing-remitting multiple sclerosis; Safety
INTRODUCTION
Multiple sclerosis (MS) is one of the most
common, autoimmune, inflammatory,
demyelinating diseases of the central nervous
system in young adults, affecting approximately
2.3 million people worldwide [1, 2]. Differences
in the risk of MS and the disease course have
been reported earlier in the Latin American
population as compared to the well-studied
Caucasian population [3–8]. For example, the
Latin American MS population has higher age at
disease onset and slower rate of progression of
disability over time [4]. Furthermore, there is
growing evidence suggestive of an increased
frequency of MS incidence in this region,
attributable mainly to the improved awareness
of the disease [4, 8]. The expansion of treatment
options for relapsing-remitting MS (RRMS),
including high efficacy agents, offers the
possibility of controlling suboptimal disease
activity [8]. The availability of ethnically
relevant clinical evidence is important for
clinical management at the individual patient
level [8].
Once-daily oral fingolimod 0.5 mg
(GilenyaTM, Novartis Pharma AG, Basel,
Switzerland) is a first-in class sphingosine
1-phosphate receptor modulator approved for
the treatment of relapsing forms of MS with a
well-characterized efficacy and safety profile in
a large clinical development program [9–12].
The safety and tolerability in the Hispanic
patients were consistent with the overall study
population in the fingolimod clinical trial
program [13]. Smaller studies at country level
in the region have provided further evidence of
the safety and tolerability of fingolimod use in
MS patients from Latin America; however, more
comprehensive data on first-dose observation
are still lacking [13–16].
The present study was aimed to provide
additional data on the short-term safety and
tolerability of fingolimod in more ethnically
relevant MS patient population in Latin
American countries.
METHODS
Study Population and Study Design
FIRST LATAM (ClinicalTrials.gov Identifier:
NCT01497262) was a 16-week, open-label,
multinational, single treatment arm, safety
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study conducted in eight countries (Argentina,
Brazil, Colombia, Mexico, Panama, Peru, Jordan
and Malaysia). Data reported here include
patients recruited at 26 centers across the Latin
American countries (excluding Jordan and
Malaysia). The study included 1–2 weeks of
screening phase to determine eligibility.
Standard 12-lead electrocardiograms (ECG) were
performed at screening and pre-dose as part of the
eligibility assessment. Eligible patients were
males and females diagnosed with RRMS using
the revised 2005 McDonald’s criteria [17].
Expanded eligibility criteria were applied to
include patients with older age (age limit
18–65 years) and high baseline Expanded
Disability Status Scale (EDSS) score range of
0–6.5. Patients with controlled diabetes mellitus
(hemoglobin A1c [HbA1c] B7%) and certain
cardiac and pulmonary conditions, excluded
from pivotal studies, were also included.
Patients with a manifestation of MS other than
RRMS, active infection, macular edema,
uncontrolled diabetes (HbA1c [7%),
immunosuppression (either drug- or disease-
induced), or had received treatment with
corticosteroids or immunoglobulins within the
previous month, or treatment with
immunosuppressive medications or monoclonal
antibodies within the previous 3 months were
not eligible for enrollment in the study. Patients
previously treated with fingolimod were not
eligible to participate. Other exclusion criteria
included any clinically significant cardiac,
pulmonary, or hepatic disease, or any
immunologic laboratory abnormalities.
All eligible patients were treated with
fingolimod 0.5 mg for 16 weeks. Upon
completion of the open-label treatment phase,
the patients had the option of entering an
extension study.
The FIRST LATAM study was conducted in
accordance with the International Conference
on Harmonization Guidelines for Good Clinical
Practice [18] and the Declaration of Helsinki
1964, as revised in 2013 [19]. The protocol was
approved by the Independent Ethics
Committee or Institutional Review Board for
each center. Each patient provided written
informed consent before enrollment.
Assessments
The primary variables of the study included the
nature and frequency of adverse events (AEs).
The safety assessments included reporting of
AEs, serious AEs (SAEs), vital signs, physical/
neurological examinations, ECG, and
laboratory examinations, and were carried out
at weeks 2, 8, and 16 (end of study visit), with
an ophthalmic examination at week 16. The
severity of AEs was defined according to the
Common Terminology Criteria (CTC) for AEs
(mild, moderate, and severe or CTC grade 1–4).
All patients received the first dose of
fingolimod and were monitored for at least 6 h
post-dose. First-dose monitoring included an
ECG at baseline and at 6 h as well as hourly
sitting heart rate (HR) and blood pressure (BP)
monitoring. Patients were asked to inform the
investigator about any cardiac symptoms or
other AEs. The initial discharge criteria after 6 h
of cardiac monitoring were: HR C51 bpm, HR
[80% of baseline value and was not the lowest
hourly value, absence of symptoms associated
with decreased HR, and ECG at 6 h showing no
new significant ECG abnormalities. During the
course of the study, following a regulatory
authority review, revisions were made to
fingolimod labeling and prescribing guidance;
consequently, amendments were made to
cardiac exclusion and first-dose discharge
criteria in the study (extended monitoring
required for HR\45 bpm, symptomatic or
received treatment for bradycardia, lowest
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hourly HR, new-onset second-degree or higher
atrioventricular block (AVB), QTc C500 ms at
6 h).
Statistical Analysis
Primary variables were summarized using
descriptive statistics. Categorical variables were
presented as numbers and percentages.
Continuous variables were summarized as
number, mean, standard deviation, and
minimum and maximum values. The ECG
parameters, vital signs and laboratory data
were summarized as mean change from
baseline values by visit. All the analyses were
performed using SAS 9.3 (The SAS Institute,
Cary, NC, USA).
RESULTS
Subject Disposition and Demographic
and Clinical Characteristics
The FIRST LATAM study enrolled 162 patients,
including the 138 patients presented here from
the Latin American countries [Argentina
(n = 31), Brazil (n = 31), Colombia (n = 19),
Mexico (n = 22), Panama (n = 10), Peru
(n = 25)]. Of these, 130 (94.2%) completed the
study and 8 (5.8%) discontinued the treatment.
The reasons for discontinuation were abnormal
laboratory values (n = 2; 1.4%), AEs (n = 1;
0.7%), abnormal test procedure results (n = 1;
0.7%), withdrawal of consent (n = 1; 0.7%), and
protocol deviation (n = 1; 0.7%). Two patients
discontinued the treatment because of
pregnancy.
The mean (±SD) age of the study population
was 37.7 (±9.4) years, 66.7% (n = 92) were
females, and 96.4% (n = 133) were of
Hispanic/Latino ethnicity. The majority of the
patients (71.0%) had received DMTs previously
which included any interferon b (55.8%),
glatiramer acetate (17.4%), azathioprine
(2.9%), natalizumab (1.4%) and other MS
medications (5.8%). The mean duration of MS
since diagnosis was 5.6 (±4.8) years, the mean
EDSS score at baseline was 2.5 (±2.0), and the
mean number of relapses in the year prior to
baseline was 1.1 (±1.0). The mean exposure to
the study drug was 117.1 (±29.1) days.
The most commonly reported medical
history and continuing medical conditions of
the enrolled patients at baseline were nervous
system disorders (32.1%), psychiatric disorders
(19.1%), surgical and medical procedures
(19.1%), infections and infestations (14.2%),
gastrointestinal disorders (11.1%), metabolism
and nutrition disorders (11.1%), eye disorders
(10.5%), and musculoskeletal and connective
tissue disorders (10.5%).
A majority of patients (66%) were on
medications or non-drug therapies prior to the
start of study drug. The most common prior
concomitant medications were gabapentin
(9.9%), paracetamol (9.9%), omeprazole
(8.0%), and cholecalciferol (5.6%).
Concomitant medications administered after
the start of study medication were taken by
80.9% of patients. The most common
concomitant medications were paracetamol
(18.5%), omeprazole (11.7%), gabapentin
(10.5%), and ibuprofen (9.9%).
Corticosteroids, like methylprednisolone and
ethylprednisolone sodium, were permitted by
the protocol for MS relapses and were received
by 3.7% and 3.1% of the patients, respectively.
Of the patients who had received prior MS
treatment (70%), most common were the
interferon beta therapies (55.6%) and
glatiramer acetate (14.8%).
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Overview of AEs and SAEs
Overall, AEs were predominantly mild (n = 49,
35.5%) or moderate (n = 27, 19.6%) in severity.
Headache and fatigue were the most commonly
reported AEs in this study. A total of 82 (59.4%)
patients experienced an AE of which seven
(5.1%) were classified as SAEs (Table 1). Of
these seven patients, treatment was continued
in six patients; one patient discontinued the
treatment because of pregnancy and reported a
spontaneous abortion in the follow-up period
after discontinuation. All SAEs were considered
unrelated to the study drug by the investigators.
Infections (overall) were reported in 33 (23.9%)
patients and were predominantly mild (n = 28,
20.3%). Herpes zoster infection was reported in
one (0.7%) patient; no case of disseminated
herpes was reported. Incidences of elevated
alanine aminotransferase of C3, C5 and C10
upper limit of normal (ULN) were reported in
five (3.7%), three (2.2%) and one (0.7%)
patients, respectively. Study drug was
permanently discontinued due to persistently
elevated bilirubin (n = 1) and gamma glutamyl
transferase (GGT) levels C2 ULN (n = 1).
However, no case of Hy’s law was reported
during the study. Overall, bradyarrhythmia AEs
were reported in 12 (8.7%) patients of which 8
events were reported post first dose (days
23–142, Table 1). Of the six cases of
bradycardia reported during the study, only
one event was reported on post first dose (day
142). This event occurred after the patient had
discontinued the study and no further records
on vital signs are available. All these events were
predominantly mild in nature and none were
serious or led to study drug discontinuation.
Mean (±SD) changes from baseline in systolic
and diastolic BP were 3.4 (±10.3) and 2.5 (±7.5)
mmHg. All three cases of hypertension (n = 3;
2.2%) were managed with antihypertensive
therapy and did not result in treatment
discontinuation. No case of macular edema
was reported in the study.
First-Dose Observations
The majority of patients (90.6%) were
discharged at 6 h (Table 2). Of the six cases of
bradycardia reported during the study, five
events were reported during the first-dose
observation period. However, none of the
patients reported symptoms of bradycardia or
required treatment for symptomatic
bradycardia. The decrease and recovery in HR
after first dose was consistent with the known
pattern for fingolimod. No new onset of second
degree or higher AVBs or prolongations in QTc
interval were detected with ECG monitoring
(protocol mandated requirements for extended
monitoring; Table 2). With continued
treatment, the mean HR returned to baseline
levels (Fig. 1) and by week 16, the decrease in
mean (±SD) HR was -1.08 (±8.66) bpm relative
to the pre-dose baseline mean value. A small
decrease in BP was observed which returned to
baseline by 6 h: peak time/mean changes
[mmHg (±SD): systolic (between 3 and 5 h)
-2.49 (±8.63) and diastolic (between 4 and 5 h)
-2.94 (±7.90)]. During the first-dose
observation, mild hypotension was reported in
one patient (mean sitting systolic/diastolic BP
was lowest at 3 h post-dose: 82.0/64.0 mmHg),
whose BP recovered to baseline by the end of
first-dose observation period (mean sitting
systolic/diastolic BP at 7 h post-dose: 100.0/
70.0 mmHg) and continued treatment. No
patient underwent extended monitoring due
to an abnormal ECG or prolonged QT interval.
Safety data from the overall study population
(n = 162) were comparable to the findings
presented here for the LATAM population
(n = 138) in the study (Data not shown).
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Urinary tract infection 4 (2.9)








Infections (total) 33 (23.9)
Inﬂuenza 4 (2.9)












Upper respiratory tract infections 2 (1.4)
Herpes infections
Oral Herpes 2 (1.4)
Genital herpes simplex 1 (0.7)
Herpes simplex 1 (0.7)
Herpes zoster 1 (0.7)
Leucopenia and lymphopenia 4 (2.9)
Thromboembolic eventsc 2 (1.4)
Malignancies (Thyroid neoplasm) 1 (0.7)
Hypertension (Mean change in BP from




Liver transaminase elevation (including
AST, ALT, Bi, GGT, AP)
5 (3.6)
AEs adverse events, ALT alanine transaminase, AP alkaline
phosphatase, AST aspartate transaminase, Bi bilirubin, BP
blood pressure, GGT gamma glutamyl transferase, N no. of
patients, SAEs serious adverse events, SD standard
deviation
a SAEs: MS relapses (n = 3; severity: 2 mild, 1 moderate);
D-ﬁbrin increased (n = 1; no associated clinical
abnormality); gastroenteritis (n = 2; severity: 1 mild, 1
severe)
b A minority of bradyarrhythmia AEs were reported after
ﬁrst dose (days 23–142): dizziness 3; bradycardia 1;
presyncope 1; malaise 2; hypotension 1
c Thromboembolic AEs: 1 (0.7%) case each of
monoparesis and angina pectoris. Monoparesis was of
moderate severity and was not suspected by the investigator
to be related to the study medication. Angina pectoris was
of mild severity, suspected to be related to study drug
medication. Neither AE resulted in study drug
discontinuation
d No. of patients for whom measurements were available
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DISCUSSION
In the FIRST LATAM study, we investigated the
short-term safety and tolerability of fingolimod
0.5 mg dose in a Latin American MS patient
population. The overall safety profile was
consistent with previous clinical trial
experience, particularly the larger FIRST study
(n = 2415) of comparable duration, with no
new or unexpected safety signals [20, 21].
Overall, fingolimod was well tolerated in the
study population. Only three patients
discontinued treatment due to AEs, of whom
two discontinued due to persistently elevated
bilirubin and GGT levels (C2 ULN) and one
discontinued due to an AE (erythema
nodosum). AEs were generally reported as mild
to moderate in nature, with the most common
AEs being headache and fatigue. The overall
nature and frequency of the AEs, including the
specific safety areas of interest (namely
infections, liver enzyme elevation, BP changes,
and macular edema) were consistent with the
previous experience [20, 21]. The majority of
infections were mild with upper respiratory
tract infections being the most common. The
incidence of herpes zoster infection was low; no
disseminated cases were reported. The reported
case of herpes zoster infection was considered
mild in severity and suspected to be related to
study drug. Patient continued on the
fingolimod and received valaciclovir
concomitantly. The infection was resolved
within 5 weeks. Liver enzyme elevations and
BP changes were clinically manageable and did
not result in treatment discontinuation. No
cases of macular edema were reported.
Table 2 First-dose observations
N5 138
(%)
Patients discharged at 6 h 125
(90.6)
Required extended monitoring after 6 ha 13 (9.4)
Reasons for extended monitoring
Lowest HR at 6 h 11 (84.6)
HR\80% of baseline value 1 (7.7)
Symptomatic/required treatment 0
ECG abnormality 0
QTc C500 ms 0








AEs adverse events, AV atrioventricular, ECG
electrocardiogram, HR heart rate, N no. of patients
a First-dose monitoring guidance was updated during the
course of the study, removing criteria for HR at discharge
must be [80% of the baseline value and for repeat
monitoring on day 2 if HR decreases by [30% from
baseline at any time during the 6-h monitoring on day 1,
and adding criteria on requirement of extended ﬁrst dose
monitoring if QTc C 500 msec at 6 h
b One patient reported dizziness alone without
bradycardia. One patient reported bradycardia and
hypotension on day 1
Fig. 1 Hourly mean change in heart rate (HR) in 6 h
following ﬁrst dose and at 4 months. SD standard
deviation
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The first dose of fingolimod, in this current
study, was well tolerated with transient, mostly
asymptomatic decreases in HR, which were
consistent with previous clinical trial
experience and are attributed to the
pharmacodynamic properties of fingolimod
[22]. The majority of patients were discharged
at 6 h, while a minority of patients underwent
extended monitoring to ensure that protocol
mandated HR recovery criteria were met. No
abnormal ECG findings were reported and no
patient discontinued treatment following the
first-dose procedure. Although, in contrast to
the larger FIRST study, bradycardia was reported
in proportionally higher number of patients in
this study (3.6% versus 0.6%) [20, 22], all of
these AEs resolved without medical treatment
on the same day.
A few other post-marketing studies have
reported the fingolimod safety experience in
Latin American populations [13–15]. A post hoc
analysis of Hispanic/Latino (n = 89) patients
from the fingolimod clinical trial program
reported similar HR changes with no reports of
symptomatic bradycardia. No patient
discontinued the treatment following the first
dose [13]. Similar to our current study, first-dose
fingolimod experience from a single Chilean
center (n = 78) was reported to be well
tolerated; there were no reports of
symptomatic bradycardia and all patients were
discharged at 6 h [15]. Similarly, the
preliminary analysis of a multi-center,
prospective study in Argentina (n = 92)
demonstrated a well-tolerated cardiac safety
profile of fingolimod. Extended monitoring
due to prolonged bradycardia was required in
three patients; however, none of the patients
developed symptomatic bradycardia [16]. In a
retrospective chart review of first-dose
experience from several Brazilian clinics
(n = 180 RRMS patients), 99.4% of patients
continued fingolimod treatment after the
initial dose, and extended monitoring due to
symptomatic bradycardia was required for 12
patients (6.7%) [14].
The results of the short-term FIRST LATAM
study provide ethnically relevant Latin
American patient data, which are consistent
with the results from the overall fingolimod
clinical trial program. Further longer term
follow-up in such patient cohorts will provide
more information to further aid clinical
decision making in Latin America.
CONCLUSION
Overall, the FIRST LATAM study demonstrates
that the first dose of fingolimod 0.5 mg is well
tolerated, the pharmacodynamic effects are
consistent with previous findings, and
fingolimod has a clinically manageable safety
profile in Latin American RRMS patients.
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